AbCellera Biologics Inc vs Broadcom Inc — how do they compare? AbCellera Biologics Inc trades at $9.06 (market cap $2.99B), while Broadcom Inc trades at $419.95 (market cap $1.98T). The key difference: Broadcom Inc is far larger — about 662.2× AbCellera Biologics Inc's market cap, and Broadcom Inc pays a 0.62% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AVGO | |
|---|---|---|
Market Cap | $2.99B | $1.98T |
Sector | Health | Technology |
52-Week High | $9.76 | $481.57 |
52-Week Low | $2.78 | $289.60 |
Enterprise Value | $2.58B | $2.02T |
Dividend Yield | — | 0.62% |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →